n(4)-hydroxycytidine has been researched along with 2019 Novel Coronavirus Disease in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 11 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agostini, ML; Baric, RS; Bluemling, GR; Brown, AJ; Chappell, JD; Denison, MR; Dinnon, KH; George, AS; Graham, RL; Harcourt, J; Hill, CS; Hughes, TM; Kolykhalov, AA; Leist, SR; Lu, X; Montgomery, SA; Natchus, MG; Painter, G; Pruijssers, AJ; Saindane, M; Schäfer, A; Sheahan, TP; Sims, AC; Stevens, LJ; Swanstrom, R; Tamin, A; Thornburg, NJ; Zhou, S | 1 |
| Beccari, AR; Cannalire, R; Cerchia, C; Di Leva, FS; Summa, V | 1 |
| Cherrington, NJ; Ekins, S; McGrath, ME; Miller, SR; Wright, SH; Zorn, KM | 1 |
| Schinazi, RF; Swanstrom, R | 1 |
| Cao, R; Chen, X; Dai, Q; Guo, X; Li, W; Li, Y; Liu, M; Wang, Z; Yan, Y; Yang, X; Zhong, W | 1 |
| Dobrovolsky, VN; McKinzie, PB; Miranda, JA; Revollo, JR | 1 |
| Ahmed, S; Hirao, Y; Kato, S; Kawanishi, S; Kobayashi, H; Mori, Y; Murata, M; Oikawa, S | 1 |
| Ahn, SB; An, YJ; Cho, JH; Choi, ER; Choi, SM; Jang, Y; Kim, M; Nam, YE; Seo, EW | 1 |
| Andrei, G; Herdewijn, P; Li, LY; Liu, C; Liu, ZP; Snoeck, R; Wang, MM; Wen, ZH | 1 |
| Ahmed, A; Bhardwaj, M; Dhiman, S; Gour, A; Khajuria, P; Manhas, D; Mukherjee, D; Nandi, U; Wazir, P | 1 |
| Gordon, CJ; Götte, M; Schinazi, RF; Tchesnokov, EP | 1 |
1 review(s) available for n(4)-hydroxycytidine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Structure; Protease Inhibitors; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |
10 other study(ies) available for n(4)-hydroxycytidine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibiotic Prophylaxis; Antiviral Agents; Betacoronavirus; Cell Line; Coronavirus Infections; COVID-19; Cytidine; Disease Models, Animal; Drug Resistance, Viral; Humans; Hydroxylamines; Lung; Mice; Mice, Inbred C57BL; Middle East Respiratory Syndrome Coronavirus; Models, Molecular; Mutation; Pandemics; Pneumonia, Viral; Primary Cell Culture; Random Allocation; Respiratory System; Ribonucleosides; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Virus Replication | 2020 |
Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Dose-Response Relationship, Drug; Drug Interactions; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; HeLa Cells; Humans; Protein Binding; SARS-CoV-2 | 2021 |
Lethal mutagenesis as an antiviral strategy.
Topics: Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; DNA; Evolution, Molecular; Genome, Viral; Humans; Hydroxylamines; Mutagenesis; Mutagenicity Tests; Phosphorylation; Ribonucleosides; RNA Virus Infections; RNA Viruses; RNA, Viral; SARS-CoV-2 | 2022 |
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.
Topics: Animals; Antigens, Viral; Antiviral Agents; Child, Preschool; COVID-19; Cytidine; Enterovirus; Enterovirus A, Human; Enterovirus Infections; Humans; Hydroxylamines; Mice; Mice, Inbred ICR | 2022 |
Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing.
Topics: Animals; COVID-19; DNA; Escherichia coli; Humans; Mammals; Mice; Mutagens; RNA, Viral; SARS-CoV-2 | 2022 |
Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
Topics: Antiviral Agents; COVID-19; DNA Damage; Humans; Hydrogen Peroxide; Hydroxylamines; Oxidative Stress; SARS-CoV-2 | 2023 |
Synthesis and biological evaluation of new β-D-N
Topics: Antiviral Agents; COVID-19; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; SARS-CoV-2; Virus Replication | 2023 |
Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
Topics: Antiviral Agents; COVID-19; Humans; Lipids; Prodrugs; SARS-CoV-2 | 2023 |
Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment.
Topics: Animals; COVID-19; Cytidine; Hydroxylamines; Rats | 2023 |
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Mutagenesis; Point Mutation; RNA, Viral; SARS-CoV-2 | 2021 |